Skip to main content
    E

    Emergent Biosolutions Inc (EBS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $5.80
    +0.02 (+0.26%)

    Market Cap: $297.69M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Emergent Biosolutions Inc (EBS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Emergent Biosolutions reported revenue of $742.90M for the fiscal year ended Dec 31, 2025, down 28.8% from the year before. That year, net income was $52.60M with a net margin of 7.1%, operating cash flow was $170.60M and free cash flow was $156.80M. The quarter ended Sep 30, 2026 had revenue of $110.00M and net income of -$32.70M.

    Revenue and Margins

    The operating margin was 13.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $488.80M, a compound annual rate of 4.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$742.90M-28.8%56.1%13.5%7.1%
    Dec 2024$1.04B-0.5%34.7%-10.4%-18.3%
    Dec 2023$1.05B+21314.3%32.8%-69.2%-72.5%
    Dec 2022$4.90M-99.9%100.0%-3469.4%-4318.4%
    Dec 2021$4.57B+189.8%67.3%7.5%4.8%
    Dec 2020$1.58B+42.6%66.0%27.8%19.4%
    Dec 2019$1.11B+41.4%60.8%10.3%4.9%
    Dec 2018$782.40M+39.5%58.8%11.5%8.0%
    Dec 2017$560.90M+14.8%66.5%22.2%14.7%
    Dec 2016$488.80MN/A74.2%21.6%10.6%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$742.90M$1.04B$1.05B$4.90M$4.57B$1.58B$1.11B$782.40M$560.90M$488.80M
    Cost of revenue$326.20M$681.30M$705.40M$0$1.50B$537.00M$433.50M$322.30M$187.70M$126.30M
    Gross profit$416.70M$362.30M$343.90M$4.90M$3.07B$1.04B$672.50M$460.10M$373.20M$362.50M
    Research and development$53.20M$70.70M$111.40M$188.30M$235.20M$237.90M$226.20M$142.80M$97.40M$106.90M
    Operating income$100.10M-$108.70M-$726.40M-$170.00M$341.40M$438.50M$114.10M$89.80M$124.30M$105.50M
    Net income$52.60M-$190.60M-$760.50M-$211.60M$219.50M$305.80M$54.50M$62.70M$82.60M$51.80M
    EBITDA$259.90M$43.70M-$499.40M-$34.30M$427.40M$561.20M$229.50M$154.50M$169.50M$145.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$110.00M$234.30M$156.10M$148.70M$231.10M$140.90M$222.20M$194.70M$293.80M$254.70M$300.40M-$755.70M
    Gross profit$29.20M$137.20M$84.10M$63.80M$145.20M$74.00M$133.70M$76.70M$171.20M-$41.40M$155.80M-$573.40M
    Operating income-$37.30M-$125.10M$10.50M-$27.90M$76.50M$1.60M$49.90M-$9.50M$64.50M-$203.50M$39.80M-$43.80M
    Net income-$32.70M-$180.20M$6.80M-$54.60M$51.20M-$12.00M$68.00M-$31.30M$114.80M-$283.10M$9.00M-$49.50M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $572.10M exceeded cash and equivalents by $366.70M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.32B$1.39B$1.82B$3.17B$2.96B$2.88B$2.33B$2.23B$1.07B$970.11M
    Current assets$662.50M$598.70M$679.50M$1.21B$1.27B$1.20B$686.20M$620.80M$485.40M$510.22M
    Cash and equivalents$205.40M$99.50M$111.70M$642.60M$576.10M$621.30M$167.80M$112.20M$178.30M$271.51M
    Total liabilities$796.00M$906.90M$1.17B$1.78B$1.35B$1.44B$1.24B$1.22B$157.90M$373.91M
    Short-term debt$0$2.70M$413.70M$957.30M$31.60M$33.80M$12.90M$10.10M$0$20.00M
    Long-term debt$572.10M$663.70M$446.50M$448.50M$809.40M$841.00M$798.40M$784.50M$13.50M$248.09M
    Shareholder equity$522.60M$482.80M$649.30M$1.39B$1.61B$1.45B$1.09B$1.01B$912.30M$596.21M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$995.20M$1.12B$1.32B$1.32B$1.46B$1.42B$1.43B$1.40B$1.48B$1.51B$1.80B$1.83B
    Total liabilities$682.00M$775.40M$797.30M$796.00M$878.50M$880.90M$873.40M$914.10M$969.40M$1.13B$1.14B$1.19B
    Cash and equivalents$175.70M$139.70M$160.30M$205.40M$245.50M$267.30M$149.10M$105.60M$149.90M$69.70M$78.50M$111.70M
    Shareholder equity$313.20M$341.40M$523.10M$522.60M$582.50M$536.20M$552.70M$482.80M$508.40M$386.30M$663.90M$649.30M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 91.9% of operating cash flow. Share repurchases came to 15.9% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$170.60M$58.70M-$206.30M-$34.10M$320.20M$536.90M$188.00M$41.80M$208.10M$54.60M
    Capital expenditures$13.80M$22.90M$51.60M$359.50M$224.10M$141.90M$86.90M$72.10M$132.40M$76.20M
    Free cash flow$156.80M$35.80M-$257.90M-$393.60M$96.10M$395.00M$101.10M-$30.30M$75.70M-$21.60M
    Dividends paidN/AN/A$5.00MN/A$15.90M$17.80M$800.00KN/A$0$0
    Share repurchases$24.90M$0$0$82.10M$106.00M$0$0$100.00K$33.10M$0
    Investing cash flow$69.40M$125.20M$212.30M-$381.30M-$224.10M-$151.90M-$96.90M-$897.20M-$249.90M-$76.20M
    Financing cash flow-$136.60M-$190.00M-$535.70M$481.20M-$141.00M$69.50M-$35.90M$788.70M-$51.40M-$19.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$100.10M$56.10M-$33.80M$77.70M-$2.30M$106.40M-$11.20M-$79.90M$153.70M$47.50M-$62.60M$32.10M
    Capital expenditures$3.30M$2.10M$2.40M$3.90M$3.40M$2.90M$3.60M$1.70M$5.80M$4.60M$10.80M$11.40M
    Free cash flow$96.80M$54.00M-$36.20M$73.80M-$5.70M$103.50M-$14.80M-$81.60M$147.90M$42.90M-$73.40M$20.70M
    Last 12 quarters

    Frequently Asked Questions About EBS

    What is Emergent Biosolutions' annual revenue?

    Emergent Biosolutions reported revenue of $742.90M for the fiscal year ended Dec 31, 2025.

    How fast is Emergent Biosolutions' revenue growing?

    Revenue was down 28.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 433.2%.

    Is Emergent Biosolutions profitable?

    Yes. Emergent Biosolutions reported net income of $52.60M for the fiscal year ended Dec 31, 2025, with a net margin of 7.1%.

    How much free cash flow does EBS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $170.60M minus capital expenditures of $13.80M produced free cash flow of $156.80M.

    How much debt does Emergent Biosolutions have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $572.10M, short-term debt of $0 and cash and equivalents of $205.40M.